2019
Lower synaptic density is associated with depression severity and network alterations
Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. Lower synaptic density is associated with depression severity and network alterations. Nature Communications 2019, 10: 1529. PMID: 30948709, PMCID: PMC6449365, DOI: 10.1038/s41467-019-09562-7.Peer-Reviewed Original ResearchConceptsMajor depressive disorderPost-traumatic stress disorderLower synaptic densitySynaptic densityPositron emission tomographyFunctional connectivityNetwork alterationsSynaptic vesicle glycoprotein 2ASymptoms of depressionSynaptic lossDepressive disorderHealthy controlsNerve terminalsDepressive symptomsDepression severityUnmedicated individualsSynaptic connectionsEmission tomographyStress disorderVivo evidenceSymptomsDepressionSeverityDisordersAlterations
2017
Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression
Esterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, Yang J, Pittenger C, Sanacora G, Krystal JH, Parsey RV, Carson RE, DeLorenzo C. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression. Molecular Psychiatry 2017, 23: 824-832. PMID: 28397841, PMCID: PMC5636649, DOI: 10.1038/mp.2017.58.Peer-Reviewed Original ResearchConceptsMajor depressive disorderMGluR5 availabilityPositron emission tomographyKetamine administrationControl groupAspartate glutamate receptor antagonistIntravenous ketamine administrationKetamine-induced reductionMetabotropic glutamatergic receptorsRapid antidepressant effectsGlutamate receptor antagonistsKetamine-induced changesEffects of ketaminePET imaging studiesMechanism of actionGlutamate surgeAntidepressant effectsAntidepressant efficacyAntidepressant responseGlutamatergic receptorsControl subjectsReceptor antagonistHealthy controlsDepressive disorderSustained decrease
2013
The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET study
Hannestad J, DellaGioia N, Gallezot JD, Lim K, Nabulsi N, Esterlis I, Pittman B, Lee JY, O’Connor K, Pelletier D, Carson RE. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET study. Brain Behavior And Immunity 2013, 33: 131-138. PMID: 23850810, PMCID: PMC3899398, DOI: 10.1016/j.bbi.2013.06.010.Peer-Reviewed Original ResearchConceptsLevels of TSPOControl subjectsSystemic inflammationPositron emission tomographyModerate depressionTSPO levelsActivation of microgliaTranslocator protein 18Total ligand bindingAcute episodePrimary outcomePostmortem studiesSevere depressionMajor depressionPET scansTSPO genotypeBrain regionsEmission tomographySubject factorsPET studiesArterial input functionInflammationElevated levelsProtein 18Depression
2012
Bupropion pre-treatment of endotoxin-induced depressive symptoms
DellaGioia N, Devine L, Pittman B, Hannestad J. Bupropion pre-treatment of endotoxin-induced depressive symptoms. Brain Behavior And Immunity 2012, 31: 197-204. PMID: 23064079, DOI: 10.1016/j.bbi.2012.10.008.Peer-Reviewed Original ResearchConceptsVisual analog scaleInflammatory cytokinesDepressive symptomsSerum levelsMontgomery-Åsberg Depression Rating ScaleSerotonin reuptake inhibitor citalopramLow-dose lipopolysaccharideReuptake inhibitor citalopramCross-over studyDepression Rating ScaleTotal MADRS scoreDopamine reuptake inhibitorInnate immune responseInnate immune systemIntravenous LPSLPS administrationReuptake inhibitorsAnalog scaleMADRS scoresHealthy subjectsImmune responseBupropionImmune systemCytokinesLPSGlucose Metabolism in the Insula and Cingulate Is Affected by Systemic Inflammation in Humans
Hannestad J, Subramanyam K, Dellagioia N, Planeta-Wilson B, Weinzimmer D, Pittman B, Carson RE. Glucose Metabolism in the Insula and Cingulate Is Affected by Systemic Inflammation in Humans. Journal Of Nuclear Medicine 2012, 53: 601-607. PMID: 22414635, PMCID: PMC3717572, DOI: 10.2967/jnumed.111.097014.Peer-Reviewed Original ResearchConceptsNormalized glucose metabolismMontgomery-Åsberg Depression Rating ScalePeak cytokine levelsSystemic inflammationDepression Rating ScaleDepressive symptomsGlucose metabolismCytokine levelsFDG-PETRating ScaleSystemic inflammatory responseCerebral metabolic rateMild depressive symptomsRight anterior cingulateTumor necrosis factorRight anterior insulaSerum levelsInflammatory cytokinesEndotoxin administrationInterleukin-6Inflammatory responseNecrosis factorCingulate subregionsHealthy subjectsInflammation
2010
Citalopram reduces endotoxin-induced fatigue
Hannestad J, DellaGioia N, Ortiz N, Pittman B, Bhagwagar Z. Citalopram reduces endotoxin-induced fatigue. Brain Behavior And Immunity 2010, 25: 256-259. PMID: 20955776, PMCID: PMC3025065, DOI: 10.1016/j.bbi.2010.10.013.Peer-Reviewed Original ResearchConceptsTumor necrosis factorMADRS total scoreDepressive-like symptomsInterleukin-6Serum levelsImmune responseMontgomery-Åsberg Depression Rating ScaleTotal scorePeripheral immune responseLow-dose endotoxinCross-over studyVisual analog scaleDepression Rating ScaleImmune system activationInnate immune responseInnate immune systemEffect sizeTrait Anxiety InventoryModerate effect sizeAnalog scaleInflammatory cytokinesEndotoxin administrationPreventive treatmentNecrosis factorHealthy subjects
2009
A critical review of human endotoxin administration as an experimental paradigm of depression
DellaGioia N, Hannestad J. A critical review of human endotoxin administration as an experimental paradigm of depression. Neuroscience & Biobehavioral Reviews 2009, 34: 130-143. PMID: 19666048, PMCID: PMC2795398, DOI: 10.1016/j.neubiorev.2009.07.014.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBrainDepressionDepressive DisorderEndotoxinsHumansInflammationModels, NeurologicalConceptsImmune system activationEndotoxin administrationSystem activationImmune stimuliDepressive symptomsInnate immune system activationElicit depressive symptomsInterferon-alpha treatmentCommon final pathwayPotential molecular pathwaysImmunologic abnormalitiesImmune depressionVaccine administrationInflammatory cytokinesDepression paradigmDepressed patientsFinal pathwaySymptomsDepression researchAdministrationDepressionMolecular pathwaysBehavioral changesActivationRodents